Komo Biosciences is pioneering next-generation precision genome engineering through the use of highly efficient, site-specific integrases. This innovative technology addresses significant limitations of existing genome editing methods, such as CRISPR, by offering a non-viral, non-nuclease approach that allows for the insertion of large DNA fragments (7-15 kb) into predetermined high-expressing regions of the human genome. The platform boasts impressive integration efficiencies, achieving up to 80% efficiency per chromosome and 96% efficiency per cell, while eliminating the risks associated with unprotected double-strand DNA breaks. This capability positions Komo's technology as a transformative solution for various applications, including cell line development, biologics manufacturing, and advanced therapies.

Komo's proprietary cell line platform, known as KOMO FT® (Fast Track), leverages these highly evolved integrases to significantly accelerate the development timelines for therapeutic products, reducing the typical duration from several months to mere weeks. This rapid turnaround is particularly crucial for therapeutic developers and government agencies focused on pandemic preparedness, where speed and precision are vital. By enhancing cell health and expression stability, Komo's technology ensures the delivery of large, complex DNA constructs, making it a valuable asset in the fields of gene therapy, veterinary medicine, and synthetic biology. Overall, Komo Biosciences is positioned to lead advancements in genome engineering, offering scalable and predictable solutions that meet the urgent needs of the life sciences sector.

United States

Komo Biosciences is a revolutionary gene editing startup that has emerged with breakthrough integrase technology from the University of Hawaii. The company has launched from stealth upon publication of groundbreaking precision genome engineering discovery.

Komo Biosciences

Company Details